Compare · AGL vs DVA
AGL vs DVA
Side-by-side comparison of agilon health inc. (AGL) and DaVita Inc. (DVA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AGL and DVA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $11.34B, about 7.0x AGL ($1.61B).
- DVA has been more active in the news (13 items in the past 4 weeks vs 8 for AGL).
- AGL has more recent analyst coverage (25 ratings vs 14 for DVA).
- Company
- agilon health inc.
- DaVita Inc.
- Price
- -
- -
- Market cap
- $1.61B
- $11.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 13
- Recent ratings
- 25
- 14
agilon health inc.
agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Long Beach, California.
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest AGL
- agilon health to Participate in Upcoming Conferences
- Chief Accounting Officer Gertsch Timothy covered exercise/tax liability with 17 shares, decreasing direct ownership by 0.12% to 14,152 units (SEC Form 4) (withholding tax)
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by agilon health inc.
- agilon health upgraded by Citigroup with a new price target
- SEC Form 10-Q filed by agilon health inc.
- agilon health inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Chief Legal Officer Zamore Denise covered exercise/tax liability with 37 shares, decreasing direct ownership by 0.06% to 66,075 units (SEC Form 4) to satisfy withholding tax
- agilon health downgraded by Citigroup with a new price target
- agilon health inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest DVA
- DaVita Announces New Value-Based Partnership with Humana to Expand Care for Patients with Chronic Kidney Disease
- Director Hollar Jason M. was granted 278 shares, increasing direct ownership by 4% to 6,883 units (SEC Form 4)
- Director Desoer Barbara J was granted 278 shares (SEC Form 4)
- Director Pullin Dennis W was granted 278 shares, increasing direct ownership by 10% to 2,949 units (SEC Form 4)
- Director Moore Gregory J. was granted 278 shares, increasing direct ownership by 4% to 8,091 units (SEC Form 4)
- Director Yale Phyllis R was granted 278 shares, increasing direct ownership by 3% to 9,803 units (SEC Form 4)
- Director Schechter Adam H was granted 278 shares, increasing direct ownership by 5% to 5,970 units (SEC Form 4)
- Director Schoppert Wendy Lee was granted 278 shares (SEC Form 4)
- Director Arway Pamela M was granted 278 shares, increasing direct ownership by 1% to 27,223 units (SEC Form 4)
- DaVita upgraded by TD Cowen with a new price target